ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0285

Improving Knowledge of Nephrologists Regarding an Emerging Class to Treat Anemia Associated with CKD

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Larkin, Amy, Medscape LLC, New York, New York, United States
  • Anderson, David R., Medscape LLC, New York, New York, United States
  • Boutsalis, George, Medscape LLC, New York, New York, United States

As emerging therapies hold promise to improve treatment of anemia in patients with CKD, clinicians need to understand mechanisms of action in order to understand the potential place in therapy when available. We sought to determine if online continuing medical education (CME) could improve the clinical knowledge of nephrologist related to emerging Hypoxia-Inducible Factor Prolyl Hyproxylase Inhibitors (HIF-PHIs).


The effect of 2 online, 30-minute, CME-certified activities were analyzed. Multiple-choice knowledge and self-efficacy confidence questions were presented both before and immediately after each activity. A repeated pairs pre-/post-assessment study design was used and chi-square test (5% significance level, P <.05) assessed educational effect. Cramer's V was used to calculate the effect size (0.06-0.15 is a noticeable effect, 0.16-0.26 considerable, and >0.26 extensive). The activity launched June 20, 2019 and data were collected through July 11, 2019.


In total, 167 nephrologists were included in the study.
Overall improvements were seen for both activities after participation:
Activity 1: N=75, P<.001, V=.156; Activity 2: N=93, P<.001, V=.162
Individual question-level improvement was also demonstrated:
21% of nephrologists (N=75, P<.05; V=.169) improved at correctly identifying the mechanism of action of HIF-PHIs
20% of nephrologists (N=75, P<.05; V=.197) improved at recognizing clinical trial data for HIF-PHIs
33% of nephrologists (N=92, P<.05; V=.315) improved at recognizing clinical trial data for HIF-PHIs
21% of nephrologists (N=93, P<.05; V=.103) improved at recognizing CVOTs for HIF-PHIs
45% (N=75) and 47% (N=92) reported increased confidence in understanding HIF PHI clinical trial data
Continued educational gaps:
55% (activity 2) and 59% (activity 1) of nephrologists did not recognize the mechanism of action of emerging HIF-PHIs
46% of nephrologists did not recognize clinical trial data for emerging HIF-PHIs
62% of nephrologists did not recognize CVOT data for emerging HIF-PHIs


This study demonstrates the success of online, video-based CME on improving knowledge of nephrologists related to emerging treatments for anemia associated with CKD. Continued knowledge gaps were identified for future educational targets.


  • Commercial Support